RT Journal Article
T1 Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
A1 Elez, Elena
A1 Gomez-España, Maria Auxiliadora
A1 Gravalos, Cristina
A1 Garcia-Alfonso, Pilar
A1 Ortiz-Morales, Maria Jose
A1 Losa, Ferran
A1 Diaz, Inmaculada Ales
A1 Graña, Begoña
A1 Toledano-Fonseca, Marta
A1 Valladares-Ayerbes, Manuel
A1 Polo, Eduardo
A1 Salgado, Mercedes
A1 Martinez de Castro, Eva
A1 Safont, Maria Jose
A1 Salud, Antonieta
A1 Ruiz-Casado, Ana
A1 Tabernero, Josep
A1 Riesco, Maria Del Carmen
A1 Rodriguez-Ariza, Antonio
A1 Aranda, Enrique
K1 Biomarkers
K1 Colorectal neoplasms
K1 Fluorouracil
K1 Vascular endothelial growth factor A
AB Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE). Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI. The reported 135 ng/mL ACE cut-off was used and ROC analysis was performed to assess the optimal VEGF-A cut-off for progression-free survival (PFS). Overall survival (OS), time to progression (TTP), time to treatment failure (TTF), overall response rate (ORR) and disease control rate (DCR) were also assessed. In total, 101 patients were followed for a median of 12 (6-17) months. The 1941 pg/mL VEGF-A was an optimal cut-off, with a longer median PFS when VEGF-A was  This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes.
PB Nature
YR 2021
FD 2021-11-09
LK http://hdl.handle.net/10668/19521
UL http://hdl.handle.net/10668/19521
LA en
NO Élez E, Gómez-España MA, Grávalos C, García-Alfonso P, Ortiz-Morales MJ, Losa F, et al. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. Br J Cancer. 2022 Apr;126(6):874-880
DS RISalud
RD Apr 6, 2025